Medindia

X

Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March

Friday, March 14, 2008 General News J E 4
Advertisement
SOUTH SAN FRANCISCO, Calif., March 13 SunesisPharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel Swisher,Sunesis' Chief Executive Officer and President, will provide a corporateoverview at two upcoming investor conferences in March.

Interested parties may access a webcast of each the presentations byvisiting the Sunesis website at http://ir.sunesis.com. A replay of thewebcasts will be archived on the "Calendar of Events" page in the Investorsand Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on thediscovery, development and commercialization of novel small-moleculetherapeutics for oncology and other serious diseases. Sunesis has built abroad product candidate portfolio through internal discovery and in-licensingof novel cancer therapeutics. Sunesis is advancing its product candidatesthrough in-house research and development efforts and strategic collaborationswith leading pharmaceutical and biopharmaceutical companies. For furtherinformation on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.-- Mr. Swisher will speak at the Cowen and Company 28th Annual Health Care Conference at 8:45 a.m. Eastern Time on Tuesday, March 18, 2008 at the Boston Marriott Copley Place in Boston, Mass. -- On Thursday, March 20, 2008, Mr. Swisher will present at the Lehman Brothers Eleventh Annual Global Healthcare Conference at 12:45 p.m. Eastern Time in Miami, Fla.

SOURCE Sunesis Pharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Boston Medical Center Meets Prescription Challenge...
S
Raven Announces Initiation of a RAV12 Phase 2 Clin...